Idorsia Ltd (SIX: IDIA) today announces the initial findings of REACT, a Phase 3 study which investigated the efficacy and safety of clazosentan in preventing clinical deterioration due to delayed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results